ZA985669B - New formulation - Google Patents

New formulation

Info

Publication number
ZA985669B
ZA985669B ZA985669A ZA985669A ZA985669B ZA 985669 B ZA985669 B ZA 985669B ZA 985669 A ZA985669 A ZA 985669A ZA 985669 A ZA985669 A ZA 985669A ZA 985669 B ZA985669 B ZA 985669B
Authority
ZA
South Africa
Prior art keywords
new formulation
formulation
new
Prior art date
Application number
ZA985669A
Other languages
English (en)
Inventor
Joanne Broadhead
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA985669(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of ZA985669B publication Critical patent/ZA985669B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA985669A 1997-07-11 1998-06-29 New formulation ZA985669B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation

Publications (1)

Publication Number Publication Date
ZA985669B true ZA985669B (en) 1999-01-11

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985669A ZA985669B (en) 1997-07-11 1998-06-29 New formulation

Country Status (35)

Country Link
US (1) US6130208A (cs)
EP (1) EP1000079B1 (cs)
JP (1) JP4950380B2 (cs)
KR (1) KR100786654B1 (cs)
CN (2) CN1864696A (cs)
AR (1) AR013157A1 (cs)
AT (1) ATE340801T1 (cs)
AU (1) AU8362598A (cs)
BR (1) BR9810703A (cs)
CA (1) CA2295628C (cs)
CY (1) CY1105805T1 (cs)
CZ (1) CZ298110B6 (cs)
DE (1) DE69836023T2 (cs)
DK (1) DK1000079T3 (cs)
EE (1) EE04119B1 (cs)
ES (1) ES2273425T3 (cs)
HU (1) HU226489B1 (cs)
ID (1) ID24716A (cs)
IL (2) IL133868A0 (cs)
IS (1) IS2439B (cs)
MY (1) MY116421A (cs)
NO (1) NO329918B1 (cs)
NZ (1) NZ502073A (cs)
PL (1) PL192768B1 (cs)
PT (1) PT1000079E (cs)
RU (1) RU2216330C2 (cs)
SA (1) SA98190328B1 (cs)
SE (1) SE9702680D0 (cs)
SI (1) SI1000079T1 (cs)
SK (1) SK285766B6 (cs)
TR (1) TR200000006T2 (cs)
TW (1) TW585764B (cs)
UA (1) UA65576C2 (cs)
WO (1) WO1999002542A1 (cs)
ZA (1) ZA985669B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986281B2 (ja) * 2004-10-05 2012-07-25 旭化成ファーマ株式会社 補酵素の安定化方法およびその組成物
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
ES2470329T3 (es) 2009-08-28 2014-06-23 Daiichi Sankyo Company, Limited Derivado del ácido 3-(biariloxi) priopi�nico
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
AU2010319612B2 (en) 2009-11-11 2016-01-14 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
CN103338754A (zh) * 2010-12-10 2013-10-02 西格玛制药实验有限责任公司 口服活性核苷酸类似物或口服活性核苷酸类似物前药的高度稳定组合物
CA2827154C (en) 2011-02-09 2020-12-29 The Medicines Company Methods for treating pulmonary hypertension
US9700347B2 (en) 2011-08-17 2017-07-11 Samuel Shiber Adaptive rotary catheter for opening obstructed bodily vessels
CA2904523C (en) 2013-03-09 2024-01-09 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
BR112017014996A2 (pt) 2015-01-14 2018-03-20 Chiesi Farm Spa formulações farmacêuticas e recipientes selados
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (cs) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
EP0619119B1 (en) * 1991-12-09 1999-03-31 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
CZ286050B6 (cs) * 1993-02-10 1999-12-15 Astra Pharmaceuticals Limited N-Alkyl-2-substituované adenosintrifostátové deriváty, způsob jejich přípravy a farmaceutické kompozice tyto deriváty obsahující
ZA949715B (en) * 1993-12-14 1996-06-06 Lilly Co Eli Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
CA2223921A1 (en) * 1995-06-07 1996-12-19 Francis C. Szoka, Jr. Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9604795D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation

Also Published As

Publication number Publication date
NO20000123D0 (no) 2000-01-10
KR20010021647A (ko) 2001-03-15
EE200000022A (et) 2000-10-16
UA65576C2 (uk) 2004-04-15
IL133868A (en) 2010-05-17
CN1263533A (zh) 2000-08-16
HUP0002622A3 (en) 2002-04-29
SK183699A3 (en) 2000-07-11
JP2001509512A (ja) 2001-07-24
SK285766B6 (sk) 2007-07-06
AR013157A1 (es) 2000-12-13
NO20000123L (no) 2000-03-03
SE9702680D0 (sv) 1997-07-11
EE04119B1 (et) 2003-08-15
CZ298110B6 (cs) 2007-06-27
NZ502073A (en) 2001-09-28
IL133868A0 (en) 2001-04-30
SA98190328B1 (ar) 2006-08-15
HK1026429A1 (en) 2000-12-15
SI1000079T1 (sl) 2007-08-31
WO1999002542A1 (en) 1999-01-21
ID24716A (id) 2000-08-03
CZ200083A3 (cs) 2000-06-14
BR9810703A (pt) 2000-08-08
AU8362598A (en) 1999-02-08
KR100786654B1 (ko) 2007-12-21
JP4950380B2 (ja) 2012-06-13
RU2216330C2 (ru) 2003-11-20
PL192768B1 (pl) 2006-12-29
HU226489B1 (en) 2009-03-02
CN1864696A (zh) 2006-11-22
DE69836023T2 (de) 2007-04-12
DE69836023D1 (de) 2006-11-09
MY116421A (en) 2004-01-31
CA2295628A1 (en) 1999-01-21
EP1000079B1 (en) 2006-09-27
PL337970A1 (en) 2000-09-11
HUP0002622A2 (hu) 2001-05-28
PT1000079E (pt) 2006-12-29
US6130208A (en) 2000-10-10
NO329918B1 (no) 2011-01-24
ATE340801T1 (de) 2006-10-15
ES2273425T3 (es) 2007-05-01
CA2295628C (en) 2008-07-29
DK1000079T3 (da) 2006-11-20
CY1105805T1 (el) 2011-02-02
IS5331A (is) 1999-12-30
TW585764B (en) 2004-05-01
IS2439B (is) 2008-11-15
EP1000079A1 (en) 2000-05-17
TR200000006T2 (tr) 2000-07-21

Similar Documents

Publication Publication Date Title
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
ZA9811461B (en) New formulation
DE69821950D1 (en) N-aroylphenylalaninderivate
GB9715751D0 (en) Formulations
GB9726916D0 (en) Nasal formulation
ZA9710601B (en) Novel formulation
ZA985669B (en) New formulation
ZA9810184B (en) New phenyl-alkyl-imidazoles
IL132989A0 (en) Carotenoid formulation
GB9724544D0 (en) Novel Formulation
GB9727518D0 (en) Use
EP0968655A4 (en) SPREAD
ZA9810773B (en) Revitalisation formulation
GB9810180D0 (en) Novel formulation
GB9706957D0 (en) Formulation
ZA976592B (en) Formulation
GB2326623B (en) Prentensioner
DE59806884D1 (en) Dexamethason-gel
GB2330366B (en) Catch-pits
DE69813798D1 (en) Multizyklische erythromycinderivate
DE69737400D1 (en) Substituierte naphthopyrane
DE69735266D1 (en) Substituierte naphthopyrane
GB2323262B (en) Snack-foods
GB9725275D0 (en) Formulation
GB9721807D0 (en) Formulation